Q4 EPS Estimates for Globus Medical Raised by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Roth Capital raised their Q4 2025 earnings per share (EPS) estimates for Globus Medical in a research note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now anticipates that the medical device company will post earnings of $0.96 per share for the quarter, up from their prior forecast of $0.91. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share.

GMED has been the subject of several other reports. Bank of America raised their price objective on Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a research note on Wednesday, November 6th. Truist Financial lifted their price target on Globus Medical from $85.00 to $90.00 and gave the stock a “hold” rating in a research note on Wednesday. Royal Bank of Canada upped their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th. StockNews.com cut shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.55.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $81.94 on Thursday. The stock has a market capitalization of $11.16 billion, a price-to-earnings ratio of 122.30, a PEG ratio of 1.99 and a beta of 1.19. Globus Medical has a 1-year low of $49.33 and a 1-year high of $87.22. The company has a 50 day moving average price of $79.78 and a 200 day moving average price of $73.23.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. During the same quarter last year, the firm posted $0.57 EPS. The business’s revenue for the quarter was up 63.1% on a year-over-year basis.

Insider Transactions at Globus Medical

In other Globus Medical news, SVP Kelly Huller sold 5,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $81.01, for a total transaction of $405,050.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. Insiders sold 97,500 shares of company stock valued at $7,674,950 in the last three months. Corporate insiders own 18.54% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

A number of large investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC bought a new stake in Globus Medical during the 2nd quarter valued at approximately $611,000. Quest Partners LLC acquired a new position in shares of Globus Medical during the third quarter worth approximately $523,000. Intech Investment Management LLC boosted its position in shares of Globus Medical by 291.3% in the third quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company’s stock valued at $1,469,000 after acquiring an additional 15,283 shares during the period. Quantbot Technologies LP bought a new stake in shares of Globus Medical in the third quarter valued at approximately $2,709,000. Finally, AXA S.A. grew its stake in shares of Globus Medical by 0.5% in the second quarter. AXA S.A. now owns 1,478,242 shares of the medical device company’s stock worth $101,245,000 after acquiring an additional 7,443 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.